Table 4 Outcome of patients treated with imatinib followed by surgery for metastatic gastrointestinal stromal tumor

Bonvalot et al., 2006 [23]

17

32*

62% 2-year OS*

Raut et al., 2006 [24]

60

14.6*

1-year OS was 95% for SD, 86% for LP, and 0% for GP†

Rutkowski et al., 2006 [25]

29

12

89.6% alive at last FU

Andtbacka et al., 2007 [20]

11

30.7‡

100% alive at last FU

24

11.8||

79% alive at last FU

Gronchi et al., 2007 [21]

27

29

100% alive at 1-year (RD)

8

12

60% alive at 1-year (PD)

DeMatteo et al., 2007 [22]

40

15**

100% alive at 2-year RD; 36% 2-year FR; 36% 1-year MR

Mearadji et al., 2008 [34]

6

46

33% alive at last FU

Mussi et al., 2010 [35]

49

31††

5-year DSS 82.9% in group A;

31

13††

5-year DSS 67.6% in group B

Raut et al., 2010 [36]

50

16.4‡‡

Median OS not reached for RD, 18.5 months for LP, 8.9 months for GP

Yen et al., 2010 [37]

35

37

2-year OS 69.6% for PR + SD; 2-year OS 48.4% for LP

Present study

55

28||||

5-year OS 78% RD, and 3-year OS 26% PD